0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Commentary |

Using Pharmacogenetics to Improve Drug Safety and Efficacy

Susanne B. Haga, PhD; Wylie Burke, MD, PhD
JAMA. 2004;291(23):2869-2871. doi:10.1001/jama.291.23.2869.
Text Size: A A A
Published online

Extract

Pharmacogenetics, the tailoring of drug treatment according to individual genotype, has been widely proclaimed as a first step toward personalized medicine. In this issue of THE JOURNAL, Chasman et al1 report the association of 2 common polymorphisms in the 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) gene with reduced efficacy of pravastatin therapy. In a survey of 148 single nucleotide polymorphisms in 10 genes involved in lipid metabolism, carriers of 2 linked SNPs in the HMGCR gene showed significantly smaller reductions in levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol with treatment. Statins, the most potent and widely used cholesterol-lowering drugs, function as competitive inhibitors of HMGCR, the rate-limiting enzyme for cholesterol synthesis. This study is the first to demonstrate the impact of genetic variation in the HMGCR drug target for this popular class of drugs, justifying the need for further study to validate and perhaps translate these findings into the clinical setting.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 24

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();